Astodrimer Sodium: meta-analysis of COVID-19 studies

All studies Hospitalization Serious outcomes Recovery Viral clearance RCTs Peer-reviewed All outcomes

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−205%

Hospitalization (1)−205%

Viral clearance (1)24%

RCTs (1)−205%

Early (1)−205%

00.511.5+

← Astodrimer
Sodium
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

c19early.org

October 2026

Astodrimer sodium COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Winchester (DB RCT)−205%3.05 · 0.13–74.02hosp.1/960/101

Early treatment−205%3.05 · 0.13–74.021/960/101205% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.5

All studies−205%3.05 · 0.13–74.021/960/101205% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.500.511.52+

Rotate screen for more detailsIncrease width for more details

← Astodrimer
Sodium
reduces riskAstodrimer
Sodium
increases risk →

c19early.org

October 2026

Astodrimer sodium COVID-19 hospitalization results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Winchester (DB RCT)−205%3.05 · 0.13–74.02hosp.1/960/101

Early treatment−205%3.05 · 0.13–74.021/960/101205% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.5

All studies−205%3.05 · 0.13–74.021/960/101205% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.500.511.52+

Rotate screen for more detailsIncrease width for more details

← Astodrimer
Sodium
reduces riskAstodrimer
Sodium
increases risk →

c19early.org

October 2026

Astodrimer sodium COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Winchester (DB RCT)−205%3.05 · 0.13–74.02hosp.1/960/101

Early treatment−205%3.05 · 0.13–74.021/960/101205% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.5

All studies−205%3.05 · 0.13–74.021/960/101205% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.500.511.52+

Rotate screen for more detailsIncrease width for more details

← Astodrimer
Sodium
reduces riskAstodrimer
Sodium
increases risk →

c19early.org

October 2026

Astodrimer sodium COVID-19 recovery results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Winchester (DB RCT)19%0.81 · 0.52–1.26no recov.23/7931/86

Early treatment19%0.81 · 0.52–1.2623/7931/8619% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.35

All studies19%0.81 · 0.52–1.2623/7931/8619% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.3500.511.52+

Rotate screen for more detailsIncrease width for more details

← Astodrimer
Sodium
reduces riskAstodrimer
Sodium
increases risk →

c19early.org

October 2026

Astodrimer sodium COVID-19 viral clearance results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Winchester (DB RCT)24%0.76 · 0.47–1.27viral+62/9673/101

Early treatment24%0.76 · 0.63–0.9262/9673/10124% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.0057

All studies24%0.76 · 0.63–0.9262/9673/10124% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.005700.511.52+

Rotate screen for more detailsIncrease width for more details

← Astodrimer
Sodium
reduces riskAstodrimer
Sodium
increases risk →

c19early.org

October 2026

Astodrimer sodium COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Winchester (DB RCT)−205%3.05 · 0.13–74.02hosp.1/960/101

Early treatment−205%3.05 · 0.13–74.021/960/101205% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.5

All studies−205%3.05 · 0.13–74.021/960/101205% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.500.511.52+

Rotate screen for more detailsIncrease width for more details

← Astodrimer
Sodium
reduces riskAstodrimer
Sodium
increases risk →

c19early.org

October 2026

Astodrimer sodium COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Winchester (DB RCT)−205%3.05 · 0.13–74.02hosp.1/960/101

Early treatment−205%3.05 · 0.13–74.021/960/101205% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.5

All studies−205%3.05 · 0.13–74.021/960/101205% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.500.511.52+

Rotate screen for more detailsIncrease width for more details

← Astodrimer
Sodium
reduces riskAstodrimer
Sodium
increases risk →

c19early.org

October 2026

Astodrimer sodium COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Winchester (DB RCT)−205%3.05 · 0.13–74.02hosp.1/960/101 Winchester (DB RCT)19%0.81 · 0.52–1.26no recov.23/7931/86 Winchester (DB RCT)24%0.76 · 0.47–1.27viral+62/9673/101

00.511.52+

Rotate screen for more detailsIncrease width for more details

← Astodrimer
Sodium
reduces riskAstodrimer
Sodium
increases risk →